The aims of the present study were: i) to establish GPC3-derived, peptide-specific CTL clones from the PBMCs of an HLA-A*02:07-positive patient with HCC who showed a PR in the phase I clinical trial; and ii) to analyze the functions of these CTL clones. Here, GPC3 is linked to hepatocellular carcinoma.